AstraZeneca (LON:AZN) Insider Acquires £303,025 in Stock

Key Points

• AstraZeneca insider Michel Demare purchased 2,500 shares at an average price of £121.21, representing a total investment of £303,025.
• The stock traded around £120.90, near its 50-day moving average of £122.84 and below its 12-month high of £157.32; it has a market capitalization of approximately £187.5 billion.
• Analysts remain generally positive, with six Buy ratings and one Hold rating. AstraZeneca has a “Moderate Buy” consensus rating and an average price target of £150.

AstraZeneca PLC (LON:AZN - Get Free Report) insider Michel Demare bought 2,500 shares of the stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of £121.21 per share, for a total transaction of £303,025.

AstraZeneca Stock Performance

LON:AZN traded down GBX 64 during midday trading on Tuesday, reaching £120.90. The stock had a trading volume of 71,305,945 shares, compared to its average volume of 32,175,939. AstraZeneca PLC has a 12-month low of £107.84 and a 12-month high of £157.32. The firm has a fifty day simple moving average of £122.84 and a two-hundred day simple moving average of £135.11. The stock has a market cap of £187.50 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.86 and a beta of 0.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Berenberg Bank dropped their price objective on shares of AstraZeneca from £160 to £150 and set a "buy" rating for the company in a research note on Tuesday. Citigroup boosted their price target on AstraZeneca from £175 to £178 and gave the stock a "buy" rating in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a £117 price objective on shares of AstraZeneca in a research note on Tuesday. Jefferies Financial Group reiterated a "buy" rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, September 9th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a £145 target price on shares of AstraZeneca in a report on Tuesday, September 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, AstraZeneca currently has an average rating of "Moderate Buy" and an average price target of £150.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.